Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 2: full-pipeline trial registry
63 of 351 indexed Diabetes Mellitus, Type 2 trials are currently recruiting.
Corpus placement: #18 of 28,707 conditions by registered trial count.
351 US clinical trials · 63 currently recruiting · #18 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 2: 351 US clinical trials tracked, 63 recruiting.
Diabetes Mellitus, Type 2 is the subject of 351 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 100 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 48 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-2
OPEN 63 | RECR 18% | LATE 100 | EARLY 80 | RANK #18 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Diabetes Mellitus, Type 2 lists 63 open slots (18% of 351 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 2 is recruiting below its size-band peers.
63 of 351 indexed trials (17.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 2 trials is spread across many organizations.
Novo Nordisk A/S accounts for 48 of 351 trials (13.7%). 143 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 2 enrolment sits around 150 participants.
Median target enrolment is 150 among the 349 trials that report a genuine target (sentinel values excluded). 142 of those (40.7%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 2 research is mostly interventional.
321 interventional and 30 observational studies make up this index (91.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
351 total, page 7 of 8
Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms
University of Washington
NCT01892124
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
The University of Texas Health Science Center at San Antonio
NCT03168295
Combining Flash Glucose Monitoring and Online Peer Support to Improve Outcomes in Hispanics With Type 2 Diabetes
University of Utah
NCT03799796
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.
Hoffmann-La Roche
NCT01017302
A Drug Interaction Study of Albiglutide and Digoxin
GlaxoSmithKline
NCT01147718
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT01177163
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
GlaxoSmithKline
NCT00501462
Mitochondrial Methylation in Type 2 Diabetes
University of Arizona
NCT04126551
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
GlaxoSmithKline
NCT00625859
A Continuous Glucose Monitor Based Insulin Bolus Calculator
Welldoc
NCT05229445
The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes
Physicians Committee for Responsible Medicine
NCT06106035
A Multi-level Intervention to Increase Access and Use of the Patient Portal
Yale University
NCT05180721
Effect of Thiazolidinedione Treatment Vascular Risk Markers
University of Arkansas
NCT00571506
Quitting Caffeine for Better Glucose Metabolism
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT01030796
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Incyte Corporation
NCT00478322
The Impact of Exercise Counseling on Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial
University of Central Arkansas
NCT00910507
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
University of Colorado, Denver
NCT03620773
Carnitine and Liver Mitochondria Fatty Acid Processing
Pennington Biomedical Research Center
NCT03193125
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
VA Office of Research and Development
NCT05205005
Diabetes Communication and Treatment Burden
University of California, Davis
NCT04568382
Behavioral Family Systems Therapy for Teens With Type 2 Diabetes
Nemours Children's Clinic
NCT05422807
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
Pennington Biomedical Research Center
NCT00402012
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
Gan and Lee Pharmaceuticals, U
NCT05328726
Health Mindset as a Driver of Efficacy of a Diabetes Prevention Program in the Blackfeet Community
Montana State University
NCT04571723
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
Halozyme Therapeutics
NCT00916357
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Novartis
NCT00380445
Afrezza® Dosing Optimization Study
Mannkind Corporation
NCT04849845
Impact of Slowly Digestible Carbohydrates on the Gut-brain Axis
Purdue University
NCT05349903
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
Novo Nordisk A/S
NCT01511185
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
Novo Nordisk A/S
NCT05689099
DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients
Daniel Amante
NCT05583877
SGLT2 Inhibition in Diabetes and Heart Failure
Virginia Commonwealth University
NCT02862067
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
Joshua M Hare
NCT02886884
Whole Grains, Gastric Emptying and Glycemic Response
Purdue University
NCT03467659
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
Northwestern University
NCT01695278
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
GlaxoSmithKline
NCT01929863
Production of Free Fatty Acids From Blood Triglycerides
Mayo Clinic
NCT00911482
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I
St. Louis University
NCT03445702
Practice Based Nutrition Intervention-2
Physicians Committee for Responsible Medicine
NCT01700868
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Novo Nordisk A/S
NCT04817644
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
Hoffmann-La Roche
NCT00461058
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
Pfizer
NCT01757756
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
GlaxoSmithKline
NCT00501930
A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
Novartis Pharmaceuticals
NCT00351507
Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study
University of Pittsburgh
NCT02081573
Low Dose Fat-Induced Insulin Resistance
University of Pennsylvania
NCT03479671
Behavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
Katherine Vickery
NCT06025721
Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)
US Department of Veterans Affairs
NCT00108225
INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers
Arizona State University
NCT04076995
OT-Led Interdisciplinary Diabetes Self-Management Prgm
Arizona State University
NCT03821662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 38 |
| Phase 3 | 74 |
| Phase 4 | 26 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 2 page
351 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 2 condition card totals 351 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.